R&G PHARMASTUDIES CO., LTD. Financials R&G PharmaStudies Co., Ltd.
Equities
301333
CNE100005K44
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.98 CNY | +2.13% |
|
+2.18% | -28.69% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 4,940 | 6,190 | 4,414 | - | - |
| Enterprise Value (EV) 1 | 4,940 | 6,190 | 4,414 | 4,414 | 4,414 |
| P/E ratio | 23.2 x | 31 x | 25.7 x | 19.2 x | 16.2 x |
| Yield | - | 0.31% | 5.28% | 6.2% | - |
| Capitalization / Revenue | - | 8.58 x | 5.1 x | 4.24 x | 3.57 x |
| EV / Revenue | - | 8.58 x | 5.1 x | 4.24 x | 3.57 x |
| EV / EBITDA | - | 28.5 x | 21.9 x | 17 x | 14.2 x |
| EV / FCF | - | - | 30.2 x | 23.9 x | 18.2 x |
| FCF Yield | - | - | 3.31% | 4.18% | 5.5% |
| Price to Book | - | 3.54 x | 2.39 x | 2.18 x | 1.9 x |
| Nbr of stocks (in thousands) | 96,000 | 96,000 | 96,000 | - | - |
| Reference price 2 | 51.46 | 64.48 | 45.98 | 45.98 | 45.98 |
| Announcement Date | 4/24/23 | 4/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 721.4 | 865.3 | 1,041 | 1,235 |
| EBITDA 1 | - | 217.1 | 201.6 | 259.6 | 310.5 |
| EBIT 1 | - | 182.5 | 198.6 | 264 | 316.1 |
| Operating Margin | - | 25.3% | 22.96% | 25.36% | 25.6% |
| Earnings before Tax (EBT) 1 | - | 182.5 | 202.3 | 266.5 | 321.6 |
| Net income 1 | 113.6 | 162.5 | 171.6 | 229.8 | 272.4 |
| Net margin | - | 22.53% | 19.83% | 22.08% | 22.06% |
| EPS 2 | 2.220 | 2.080 | 1.790 | 2.392 | 2.835 |
| Free Cash Flow 1 | - | - | 146.3 | 184.3 | 242.7 |
| FCF margin | - | - | 16.91% | 17.71% | 19.66% |
| FCF Conversion (EBITDA) | - | - | 72.56% | 70.99% | 78.17% |
| FCF Conversion (Net income) | - | - | 85.27% | 80.19% | 89.11% |
| Dividend per Share 2 | - | 0.2000 | 2.430 | 2.850 | - |
| Announcement Date | 4/24/23 | 4/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 146 | 184 | 243 |
| ROE (net income / shareholders' equity) | - | 9.75% | 9.71% | 11.4% | 11.8% |
| ROA (Net income/ Total Assets) | - | 8.22% | 7.83% | 9.45% | 10% |
| Assets 1 | - | 1,978 | 2,190 | 2,432 | 2,725 |
| Book Value Per Share 2 | - | 18.20 | 19.30 | 21.10 | 24.20 |
| Cash Flow per Share 2 | - | 2.010 | 1.700 | 2.610 | 2.970 |
| Capex 1 | - | 19.9 | 17.2 | 16.6 | 23.8 |
| Capex / Sales | - | 2.75% | 1.99% | 1.59% | 1.93% |
| Announcement Date | 4/24/23 | 4/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
45.98
CNY
Average target price
60.5
CNY
Spread / Average Target
+31.58%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.69% | 610M | |
| +18.63% | 84.11B | |
| +2.04% | 27.25B | |
| -9.66% | 17.31B | |
| -1.96% | 16.83B | |
| +3.96% | 15.92B | |
| +7.75% | 13.68B | |
| +72.83% | 13.29B | |
| +72.50% | 12.73B | |
| +2.50% | 12.62B |
- Stock Market
- Equities
- 301333 Stock
- Financials R&G PharmaStudies Co., Ltd.